Vonoprazan, aspirin and NSAIDs: new era in acid inhibition and gastroprotection

Comment

Ali S Taha. Gut. 2018 Jun.

. 2018 Jun;67(6):995-996.

doi: 10.1136/gutjnl-2017-315252. Epub 2017 Dec 5.

No abstract available

Keywords: acid; aspirin; drug development; gastric and duodenal ulcers; proton pump inhibition.

Conflict of interest statement

Competing interests: None declared.

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, Ashida K, Sugano K. Mizokami Y, et al. Gut. 2018 Jun;67(6):1042-1051. doi: 10.1136/gutjnl-2017-314010. Epub 2017 Oct 7. Gut. 2018. PMID: 28988197 Free PMC article. Clinical Trial.
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, Ashida K, Sugano K. Kawai T, et al. Gut. 2018 Jun;67(6):1033-1041. doi: 10.1136/gutjnl-2017-314852. Epub 2017 Dec 1. Gut. 2018. PMID: 29196436 Free PMC article. Clinical Trial.